Indian Journal of Drugs in Dermatology

: 2021  |  Volume : 7  |  Issue : 2  |  Page : 51--59

IL-23 blockers in dermatology

Shrichand G Parasramani1, Manasi Shirolikar2 
1 Department of Dermo-Cosmetology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India
2 Kaya Skin Clinic, Mumbai, Maharashtra, India

Correspondence Address:
Shrichand G Parasramani
Anisha Clinic, Mangal Sudha, SV Road, Khar, Mumbai 400052, Maharashtra

Interleukin-23 (IL-23) is the key regulatory cytokine in psoriasis, which stimulates differentiation, proliferation, and survival of T-helper 17 (Th17) cells. Specific targeting of IL-23–IL-17 inflammatory pathway has become an effective therapeutic approach to treat psoriasis. Clinical studies have shown that antibodies directed against the p19 subunit of IL-23 show equal or superior response as compared to when both IL-12 and IL-23 are inhibited. Side effects of IL-12 inhibition are avoided. Tildrakizumab, guselkumab, and risankizumab are antibodies that target the p19 subunit of IL-23. These newer IL-23 blockers give high PASI response and are easy to administer once in 8–12 weeks. A comparison of these three drugs from different trials is carried out in this review with the help of bar charts. There are no head-to-head comparative trials of these monoclonal antibodies.

How to cite this article:
Parasramani SG, Shirolikar M. IL-23 blockers in dermatology.Indian J Drugs Dermatol 2021;7:51-59

How to cite this URL:
Parasramani SG, Shirolikar M. IL-23 blockers in dermatology. Indian J Drugs Dermatol [serial online] 2021 [cited 2022 Jan 25 ];7:51-59
Available from:;year=2021;volume=7;issue=2;spage=51;epage=59;aulast=Parasramani;type=0